Cited 23 times in
Atypical teratoid/rhabdoid tumors in children treated with multimodal therapies: The necessity of upfront radiotherapy after surgery
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이정심 | - |
dc.contributor.author | 김동석 | - |
dc.contributor.author | 한정우 | - |
dc.contributor.author | 서창옥 | - |
dc.date.accessioned | 2023-08-09T02:48:55Z | - |
dc.date.available | 2023-08-09T02:48:55Z | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 1545-5009 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195864 | - |
dc.description.abstract | Background: Atypical teratoid/rhabdoid tumor (ATRT) is a rare malignant pediatric brain tumor with a dismal prognosis. We evaluated the efficacy of multimodal therapy in children with ATRT. Procedure: Nine children diagnosed with cranial ATRT, who received multimodal therapy between 2005 and 2014, including surgical resection followed by radiotherapy (RT), systemic chemotherapy (CT), and high-dose chemotherapy/stem cell transplantation (HDCT/SCT), were analyzed retrospectively. The median age at diagnosis was 32 months. Initial treatment included surgery in eight patients (88%), CT in all (100%), RT in eight (88%), and HDCT/SCT in seven (78%). Results: The median follow-up period for survivors was 21 months. The 2-year progression-free rate was 66.7%. Two patients had progression 4 and 17 months after diagnosis. One received multimodal treatment, including surgery and upfront CT with delayed RT; the other underwent surgery and upfront CT without RT. The 2-year event-free survival and overall survival rates were 46.7% and 62.2%, respectively. Hematologic toxicity of grade 3 or more was observed in six patients treated with HDCT/SCT and two who underwent craniospinal irradiation. Deaths were attributed to progressive disease (n = 2) and treatment-related toxicity (n = 2) from sepsis and acute respiratory failure after CT and HDCT/SCT. Conclusions: Maximal safe resection in conjunction with upfront RT is a reasonable multimodal treatment in patients with ATRT for prolonging progression-free survival. Further research may help determine the optimal parameters for reducing treatment toxicity, such as intensity of HDCT/SCT and the RT field. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | John Wiley | - |
dc.relation.isPartOf | PEDIATRIC BLOOD & CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Brain Neoplasms / mortality | - |
dc.subject.MESH | Brain Neoplasms / therapy* | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Child, Preschool | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Disease Progression | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infant | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Rhabdoid Tumor / mortality | - |
dc.subject.MESH | Rhabdoid Tumor / therapy* | - |
dc.subject.MESH | Stem Cell Transplantation | - |
dc.title | Atypical teratoid/rhabdoid tumors in children treated with multimodal therapies: The necessity of upfront radiotherapy after surgery | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Jeongshim Lee | - |
dc.contributor.googleauthor | Dong-Seok Kim | - |
dc.contributor.googleauthor | Jung Woo Han | - |
dc.contributor.googleauthor | Chang-Ok Suh | - |
dc.identifier.doi | 10.1002/pbc.26663 | - |
dc.contributor.localId | A03112 | - |
dc.contributor.localId | A00402 | - |
dc.contributor.localId | A04325 | - |
dc.contributor.localId | A01919 | - |
dc.relation.journalcode | J02479 | - |
dc.identifier.eissn | 1545-5017 | - |
dc.identifier.pmid | 28598565 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/pbc.26663 | - |
dc.subject.keyword | atypical teratoid/rhabdoid tumor | - |
dc.subject.keyword | multimodal therapy | - |
dc.subject.keyword | pediatric brain tumors | - |
dc.subject.keyword | radiotherapy | - |
dc.contributor.alternativeName | Lee, Jeong Shim | - |
dc.contributor.affiliatedAuthor | 이정심 | - |
dc.contributor.affiliatedAuthor | 김동석 | - |
dc.contributor.affiliatedAuthor | 한정우 | - |
dc.contributor.affiliatedAuthor | 서창옥 | - |
dc.citation.volume | 64 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | e26663 | - |
dc.identifier.bibliographicCitation | PEDIATRIC BLOOD & CANCER, Vol.64(12) : e26663, 2017-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.